MedTrace Logo

Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma

NCT05002621 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).

Conditions

Interventions

OTHER

Observational

Enrolled patients had a prescription for mepolizumab provided during the course of routine clinical care, and enrollment occurred prior to the initiation of mepolizumab.

Sponsors & Collaborators

Principal Investigators

  • Thanai Pongdee, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2023-02-13
Completion
2025-12-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05002621 on ClinicalTrials.gov